Invalidity dossier
US 10870661
Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity
Current assignee: Shionogi and Co Ltd
Added 9/21/2026, 9:33:05 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US10870661B2
Title: Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity
Patent number: US10870661B2 (application US16/665,231; earlier publication US20200055873A1)
Assignee: Shionogi and Co Ltd (original and current assignee as listed)
Inventors: Yoshinori Tamura, Shuichi Sugiyama, Akira Matsumura, Toshiyuki Akiyama, Yutaka Tomida
Key dates: Priority date 2015-05-29; filing date 2019-10-28; publication date 2020-12-22; anticipated expiration 2036-05-27. Legal status shown as "Expired - Fee Related" (the source notes legal status is an assumption, not a legal conclusion).
Purpose: The compounds are nitrogen-containing tricyclic derivatives described as having HIV replication inhibitory activity.
Plain-language scope: The excerpt centers on a Markush-type chemical formula whose core is a tricyclic ring system containing nitrogen:
[1*]C1=CC2=C(cc([4])(B[4*])N2)C([3*])=C1C(C)C(=O)O[4*]
The listed prior-art keywords — substituted, aromatic, unsubstituted, alkyl, compound — indicate that substituent variation (substituted or unsubstituted aromatic and alkyl groups) is central to the claimed chemical space. The specification excerpt provides numerous specific example compounds, many featuring a p-chlorophenyl or p-fluorophenyl substituent, a methyl-substituted ring nitrogen, a piperazine or related nitrogen-containing ring, and a C@HC(=O)O side chain (a tert-butoxy-substituted carboxylic acid), consistent with the recited generic formula. Several examples carry sulfonyl, carbamoyl, pyrimidinyl, or pyridyl substituents on the ring nitrogen.
What the excerpt does not establish: Because the text is truncated, this overview cannot state the full claim set, the exact number and wording of the claims, the complete Markush definitions for R1, R3, R4, A, or B, the full Markush structure, or any biological or assay data (for example IC50 values or viral inhibition results). It also does not establish the total number of examples or any additional embodiments. No assertions are made here about litigation, ownership transfers, validity, or prior art.
Source: https://patents.google.com/patent/[US10870661](/patent/US10870661)/en
Generated 10/1/2026, 10:02:10 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 10870661. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.